WO1997000881A1 - Derives de la moranoline - Google Patents
Derives de la moranoline Download PDFInfo
- Publication number
- WO1997000881A1 WO1997000881A1 PCT/JP1996/001730 JP9601730W WO9700881A1 WO 1997000881 A1 WO1997000881 A1 WO 1997000881A1 JP 9601730 W JP9601730 W JP 9601730W WO 9700881 A1 WO9700881 A1 WO 9700881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- substituted
- sodium salt
- moranoline
- Prior art date
Links
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical class OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 180
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 55
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 15
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 13
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000001424 substituent group Chemical group 0.000 claims abstract description 12
- 125000004442 acylamino group Chemical group 0.000 claims abstract description 11
- 229910052751 metal Chemical class 0.000 claims abstract description 11
- 239000002184 metal Chemical class 0.000 claims abstract description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 7
- 125000004104 aryloxy group Chemical group 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 60
- -1 alkoxycarbol Chemical group 0.000 claims description 53
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 150000001350 alkyl halides Chemical class 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- ZXYFGZNMDRNOGQ-UHFFFAOYSA-N ac1lawgt Chemical compound [S]O ZXYFGZNMDRNOGQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 241001553014 Myrsine salicina Species 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 4
- 125000002252 acyl group Chemical group 0.000 abstract description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 208000028867 ischemia Diseases 0.000 abstract description 3
- 125000003342 alkenyl group Chemical group 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 125000000020 sulfo group Chemical class O=S(=O)([*])O[H] 0.000 abstract description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 2
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 60
- 230000015572 biosynthetic process Effects 0.000 description 51
- 239000011734 sodium Substances 0.000 description 51
- 238000003786 synthesis reaction Methods 0.000 description 50
- 125000004432 carbon atom Chemical group C* 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 38
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 37
- 239000000203 mixture Substances 0.000 description 36
- 239000000843 powder Substances 0.000 description 35
- 239000000243 solution Substances 0.000 description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- 238000000921 elemental analysis Methods 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 238000004440 column chromatography Methods 0.000 description 22
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 19
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 15
- 229910052708 sodium Inorganic materials 0.000 description 15
- 238000010828 elution Methods 0.000 description 11
- 239000003480 eluent Substances 0.000 description 10
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000007995 HEPES buffer Substances 0.000 description 9
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 9
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 9
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 8
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 8
- 230000021164 cell adhesion Effects 0.000 description 8
- 230000001464 adherent effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 7
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 150000004678 hydrides Chemical class 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 4
- 150000004044 tetrasaccharides Chemical class 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000005630 sialyl group Chemical group 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 102000015689 E-Selectin Human genes 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 2
- 229940069417 doxy Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000976 ink Substances 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- QWOKKHXWFDAJCZ-UHFFFAOYSA-N octane-1-sulfonamide Chemical compound CCCCCCCCS(N)(=O)=O QWOKKHXWFDAJCZ-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- PJRGDKFLFAYRBV-UHFFFAOYSA-N 2-phenylthiophene Chemical compound C1=CSC(C=2C=CC=CC=2)=C1 PJRGDKFLFAYRBV-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- 125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 description 1
- OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- HBBOZFUQJDYASD-UHFFFAOYSA-N Cis-1,3-Dioxide-1,3-Dithiane Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1NC(C)=O HBBOZFUQJDYASD-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical group CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 150000001218 Thorium Chemical class 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- JLUISVZZJCWEDL-JJKGCWMISA-N [Na].N=C([C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)O Chemical compound [Na].N=C([C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)O JLUISVZZJCWEDL-JJKGCWMISA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940067621 aminobutyrate Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- DKZBBWMURDFHNE-NSCUHMNNSA-N coniferyl aldehyde Chemical compound COC1=CC(\C=C\C=O)=CC=C1O DKZBBWMURDFHNE-NSCUHMNNSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000040 effect on leukemia Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ULITUPMHIDVLLV-UHFFFAOYSA-N formonitrile;sodium Chemical compound [Na].N#C ULITUPMHIDVLLV-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- IBDXZWQCLMSDKQ-FDXOKOSPSA-N i-cholesterol Chemical compound C([C@H]1[C@@H]2CC[C@@H]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)[C@H](C)CCCC(C)C)[C@@H](O)[C@@]31[C@H]2C3 IBDXZWQCLMSDKQ-FDXOKOSPSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- VZORGPCQYCYZLZ-UHFFFAOYSA-E nonasodium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VZORGPCQYCYZLZ-UHFFFAOYSA-E 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 description 1
- BZCDKOOXCPRISF-UHFFFAOYSA-N o-(2-phenylethyl)hydroxylamine Chemical compound NOCCC1=CC=CC=C1 BZCDKOOXCPRISF-UHFFFAOYSA-N 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002092 orthoester group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- HPOKESDSMZRZLC-UHFFFAOYSA-N propan-2-one;hydrochloride Chemical compound Cl.CC(C)=O HPOKESDSMZRZLC-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003132 pyranosyl group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- DKZBBWMURDFHNE-UHFFFAOYSA-N trans-coniferylaldehyde Natural products COC1=CC(C=CC=O)=CC=C1O DKZBBWMURDFHNE-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Definitions
- the present invention relates to a novel moranoline derivative which is useful as a therapeutic agent in the field of medicine, for example, an anti-inflammatory agent “prevention of ischemia and reperfusion injury”.
- High-chain compounds such as sialic acid-containing glycolipids and glycoproteins have hormone, bacterial toxin, virus and other receptor functions, and also recognize, differentiate, grow, adhere, cancer, immunize, and age cells. It is a substance that has attracted attention because it is deeply involved in basic and dynamic life phenomena such as. In particular, sialyl Lewis type ⁇ chains containing sialic acid have useful physiological activities, and their application to pharmaceuticals is being actively studied.
- sialyl Lewis type ⁇ chain derivative has a basic structure of a tetrasaccharide of sialic acid, galactose, dalcosamine and fucose, and its production requires many steps and complicated operations. For this reason, there has been a problem in conducting economical and efficient mass production of sialyl Lewis type sugar chain derivatives on an industrial scale.
- sialic acid derivatives exist as trace components in the natural world, it has been extremely difficult to obtain them as pure single compounds from living organisms. Therefore, research on the application of sialic acid derivatives to pharmaceuticals has attracted much attention as a new research field.
- the present inventors have filed an international application for a trisaccharide-type Lewis-type sugar chain derivative containing moranoline obtained by mimicking sialic acid with hydroxysulfol (PCT / JP95 / 00610).
- the compound according to the applicant's invention has moranolin instead of glucosamine, and is structurally different from the compound according to the invention of the above-mentioned natural sugar chain derivative using dalcosamine as a constituent sugar. is there,
- An object of the present invention is to provide a trisaccharide hydroxysulfur Lewis-type moranoline derivative which is a novel substance useful as a medicament described below and an intermediate useful for producing the same.
- R 1 is phenyl, alkoxycarbonyl, cyano, alkylrubamoyl, butyr, acylamino, alkylthio, alkanesulfonamide, alkoxyalkoxyalkoxyamide, aralkyloxyamide, hydroxyl group Or a lower alkyl substituted with aryloxy, a benzene ring having a hydroxyl group, alkoxy, alkyl, halogen, halogenated alkyl, cyano, rubamoyl, mono- or dialkyl rubamoyl, nitro, acylamino, alkylthio, mono- or dialkylamino Or phenyl-lower alkyl, which may be substituted with 1 to 3 substituents selected from carboxy, and 3 substituted with alkyl. May be a lower alkyl substituted with a 5-membered unsaturated heterocyclic ring, alkaryl, alkarylalk
- the lower alkyl of the lower alkyl substituted with aryloxy is preferably a straight-chain or branched-chain lower alkyl having 1 to 6 carbon atoms.
- Examples of the file include those having 1 to 6 carbon atoms. Those having 3 to 5 carbon atoms are preferred, and propioyl, valeryl and vivaloyl are preferred.
- alkoxycarbonyl examples include alkoxy having an alkyl portion having 1 carbon atom. Alkoxy having 1 to 3 carbon atoms is preferred, and methoxycarbyl, ethoxycarbol, and propoxycarbonyl are particularly preferred.
- alkyl carpamoyl examples include those having an alkyl moiety of 1 to 7 carbon atoms, preferably an alkyl moiety having 1 to 3 carbon atoms, preferably methylcarbamoyl, ethylcarbamoyl, and propyllimubamoyl. .
- acylamino examples include those having 1 to 6 carbon atoms. Those having 2 to 4 carbon atoms are preferred, and acetamide, propio-lamino and petyrylamino are preferred.
- alkyl group an S-chain or branched alkylthio group having 1 to 6 carbon atoms is preferable.
- alkane portion of the alkane sulfonamide include alkanes having 1 to 20 carbon atoms. Alkanesulfonamides having an alkane having 5 to 15 carbon atoms are preferred, and decanesulfonamide, nonanesulfonamide and octanesulfonamide are particularly preferred.
- alkoxy moiety of the alkoxyalkoxyalkoxyamide include alkoxy having 1 to 6 carbon atoms. Alkoxy having 1 to 3 carbon atoms is preferable. Preference is given to toxamide, ethoxyxethoxyethoxyamide and propoxypropoxypropoxyamide.
- aralkyl moiety of aralkyl oxyamide examples include those having 7 to 20 carbon atoms, and those having an aralkyl moiety having 7 to 9 carbon atoms are preferable. Benzoxy amide, phenethyloxy amide, phenyl ⁇ Poxyamide is preferred.
- the aryloxy includes those having 6 to 20 carbon atoms. Those having 6 to 10 carbon atoms are preferred, and phenoxy and naphthoxy are preferred.
- the benzene ring is a hydroxyl group, alkoxy, alkyl, halogeno, alkyl halide, cyano, rubamoyl, mono- or di-alkyl rubamoyl, ethopen, acylamino, alkylthio, mono or dialkyl
- Alkyl having 1 to 3 carbon atoms is preferred, and methyl, ethyl, propyl and isopropyl are preferred.
- straight-chain ⁇ includes a branched ⁇ 1 to 6 alkoxy. Those having 1 to 3 carbon atoms are preferred, and methoxy, ethoxy and propoxy are preferred.
- alkyl substituted on the benzene ring examples include a linear or branched alkyl having 1 to 6 carbon atoms. Those having 1 to 3 carbon atoms are preferred, and methyl, ethyl, propyl and isopropyl are preferred.
- alkyl in the halogenated alkyl examples include a straight-chain or branched-chain alkyl having 1 or more carbon atoms. Those having 1 to 3 carbon atoms are preferred, and trifluoromethyl is preferred.
- the mono- or di-alkyl radicals include alkyls having 1 to 6 carbon atoms which are linear or branched. Alkyl having 1 to 3 carbon atoms is preferred, and methylcarbamoyl, dimethylcarbamoyl, ethylcarbamoyl and propylcarbamoyl are preferred.
- acylamino examples include those having 1 to 6 carbon atoms. Those having 2 to 4 carbon atoms are preferred, and acetamide, propionylamino and butyrylamino are preferred.
- alkylthio a straight-chain or branched alkylthio having 1 to 6 carbon atoms is preferable.
- examples of the mono- or dialkylamino alkyl include a straight-chain or branched-chain alkyl having 1 to 6 carbon atoms.
- Alkyl having 1 to 3 carbon atoms is preferable, and methylamino, dimethylamino, ethylamino, ethylmethylamino, and propylamino are preferable.
- the benzene ring represented by R 1 is a hydroxyl group, an alkoxy, an alkyl, a halogenated halogenated alkyl, a cyano, a carbamoyl, a mono- or dialkylcarbamoyl, a utro, an acylamino, an alkylthio, a mono- or dialkylamino or a carboxy group
- phenyl lower alkyl which may be substituted with 1 to 3 substituents selected from: ⁇ -trifluoromethylphenyl, 4- (m-dimethylaminophenyl) Butyl, 5- (m-cyanoferyl) pentyl, 6- ( ⁇ -potamoylphenol) hexyl, 3.
- 5-membered unsaturated heterocyclic ring which may be substituted with alkyl, furfuryl, 5-methyl-furfuryl, 2-tur and 5-methyl-2-thenyl are preferable.
- examples of the dialkar represented by R 1 include linear or branched ones having 2 to 35 carbon atoms. Bull, Aryl, Isobutel, Pentyl, Hexyl, Oleil, Linoleyl, Arakidurnoxenyl are preferred.
- examples of the reels represented by R 1 include ferrule and naphthyl.
- Suchiri Le as ⁇ preferred examples include those described above as alkenyl, cinnamyl is.
- the primary alkyl represented by R 1 includes linear or branched alkyl having 7 to 36 carbon atoms. Those having 7 to 30 carbon atoms are preferred, and octyl, decyl, lauryl, myristyl, hexadecyl, stearyl, eicosyl and 2-tetradecylhexydecyl are preferred.
- Alkali metals and alkaline earth metal salts are exemplified as the metal salts of the hydroxysulfols represented by R 2 and R 3 , and lithium salts, sodium salts and potassium salts are preferred as the alkaline metal salts.
- As the alkaline earth metal salts magnesium salts, calcium salts, and barium salts are preferable.
- n represents an integer of 1 to 10. Among them, those having 6 or less are preferable.
- R 2 and are the same as described above.
- R 5 and R 6 are the same or different and each represent a linear or branched lower alkyl having 1 to 6 carbon atoms, preferably methyl, ethyl, propyl, and butyl.
- R J , R 3 and are the same as described above.
- 1 , R 31 and 1 represent those described above as R 2 , R 3 and respectively.
- x: represents an anion. Specifically, there are ⁇ ⁇ , cr, cr.
- the compound of the present invention represented by the following general formula [1V] S ⁇ [V] is an important intermediate for producing the compound of the present invention represented by formula [I], This is a new substance not described.
- the desired compound can be produced by introducing a desired substituent into the nitrogen atom of moranoline represented by the formula [IV], and then deacylating it.
- R 7 are different from each other and represent 4-0-acetyl-2,6-di-0-benzoyl-3-0-sulfo- ⁇ -D-galactova / sil or ⁇ -L-fucoviranosyl.
- Is asiloki represents cysteine or acetamide.
- the acyl represented by R 9 is not limited as long as the reactivity is not hindered, and examples thereof include those described above as the acyl and benzoyl.
- Examples of the acyloxy represented by R 10 include those having 1 to 10 carbon atoms. Those having 2 to 7 carbon atoms are preferred, and acetoxy, propio-loxy, petyryloxy and benzyloxy are preferred.
- an aldehyde compound having a desired substituent [R 11] CHO (R 111 is obtained by removing 0% of the base from R 1 , R 5 or R 6 above) and is a representative)] or those halides [R l X (R 1 is as defined above, X is reacted with a halogen)]
- a method of introducing a substituent into Moranori emissions of N Iyako is a special reagent Since the compound according to the present invention can be produced without the necessity, it can be carried out more economically than before.
- R 1 R 1 2 represents 3-0-3 ⁇ 4l--Dl-galatatovirane, or Pio, 3,4-tri-0-, iV-a -Ll-fucohi.
- R 1 (5 is the same as described above.
- Examples of the compound according to the present invention include the following compounds in addition to the compounds described in Examples described later, but these are only examples of some of the compounds of the present invention. However, the present invention is not limited to this.
- Higaral Ml-3 H (aL-fucovirano): K1 ⁇ ) K H3 ⁇ 2 Si 'human' t 7) a D Pilt 1,5- / Te '-1,5-imino-higurushi Sodium sodium salt
- the compound according to the present invention can be produced by the following synthesis scheme),
- Compound (1) which is a starting material shown in the scheme, can be synthesized by a method applied by the present applicant (Japanese Patent Application No. 7-106257).
- This compound is reacted with, for example, trimethyl orthoacetate in benzene under the acidity of D, L-camphor-10.sulfonate at room temperature to form an orthoester group at the 3- and 4-hydroxyl groups of the galactose residue.
- a compound (1 ′) in which the 4-position hydroxyl group of the galactose residue is selectively acetylated by acid hydrolysis in an 80% aqueous solution of lactic acid, a mixed solvent of THF and methanol is obtained. .
- Compound (2) is prepared by reacting compound ( ⁇ ) with pyridine-sulfur trioxide complex in, for example, ⁇ , ⁇ -dimethylformaldehyde (DMF) at room temperature to sulfonate the 3-position hydroxyl group of galactose residue. Then, the benzyl group and benzyloxycarbol group of the compound (2) are contacted in an alcohol at 20 to 60 ° C. for 2 to 72 hours in the presence of a catalyst such as palladium chloride black. The compound is deprotected by reduction to obtain compound (3), which is reacted with sodium cyanoborohydride and various aldehydes of the desired substituent at pH 3 to 4, for example, in methanol.
- DMF dimethylformaldehyde
- the compound (4) Can be obtained, for example, by treating this with an alkali such as sodium methylate in methanol to remove the acetyl group and the benzoyl group, thereby obtaining the compound according to the present invention. (5 ') is obtained.
- compound (3) is treated with an alkali in methanol to deprotect the acetyl group and benzoyl group to give compound (6), which is then treated with sodium cyanoborohydride in methanol and various compounds.
- an appropriate base such as potassium carbonate in N-dimethylformamide
- Moranoline residue has fucopyranosyl residue at position 3 and galactoviranosyl residue at position 4
- Carbonitrile oxygen atom of the nitrogen atom and 6-position of Moranorin as Moranorin compounds of ⁇ further following scheme can also be performed prepared above and the same reaction step for derivative (35) - intermediate crosslinked Le
- the compound according to the present invention can be produced by another method via An example of the synthesis will be described below using an example of a Lewis ⁇ -type derivative, but a Lewis X-type derivative can be produced in the same manner as this production method.
- the compound (33) is acetylated and sulfonated in the same manner as in Scheme 1 to obtain the compound (34) .
- the benzoyl group and the acetyl / re group of the compound (34) are converted into, for example, 10 to 60 with alkali in methanol.
- Deprotection by treatment at 2 ° C. for 2 to 12 hours gives compound (35)
- the benzyl group of compound (35) is deprotected, for example, by catalytic reduction in the presence of a palladium catalyst.
- Compound (36) is obtained.
- Compound (37) is obtained, for example, by subjecting compound (36) to hydrolysis in an aqueous methanol solution.
- Compound (37) can be prepared, for example, by reacting sodium cyanoborohydride and the target aldehyde in methanol at pH 3 to 4 as in Scheme 1, or by reacting an alkyl halide to form a molanolin residue.
- the compound of the present invention which is an N monosubstituted product, is obtained.
- compound (35) is hydrolyzed at 80 to 100 ° C in an aqueous methanol solution, and sodium borohydride and various aldehydes in methanol are allowed to act at pH 3 to 4,
- the present invention can also be obtained by deriving an N-substituted moranoline residue and then deprotecting the benzyl group by, for example, catalytic reduction in the presence of a palladium carbon catalyst.
- the measurement temperatures of specific rotations are all 20 ° C.
- the assembler used was MICRO ACILYZERS1 manufactured by Asahi Kasei Corporation, and AG110 was used for the cartridge unless otherwise noted.
- the aqueous layer was decompressed under reduced pressure, subjected to Karaku D matogelaphy (UChroprep RP18, eluate; water), desalted with Asilisa '-, dried to dryness, and 730 mg of compound (6) as a white powder (730 mg (83.5% )Obtained.
- Karaku D matogelaphy Uhroprep RP18, eluate; water
- Asilisa '- dried to dryness
- Example 4 The same reaction as in Example 4 was carried out using m-7' ⁇ -m-'n'-n-n'-l-'n'-arte'-human '(157 mg) to obtain 52 mg (40,8%) of the desired compound (10) as a white powder.
- m-7' ⁇ -m-'n'-n-n'-l-'n'-arte'-human '(157 mg) was carried out using m-7' ⁇ -m-'n'-n-n'-l-'n'-arte'-human '(157 mg) to obtain 52 mg (40,8%) of the desired compound (10) as a white powder.
- Example 11 The same reaction as in Example 11 was carried out using 100 mg of compound (3) and 22% (33%) of the compound (17) was obtained as a white powder.
- Example 3 The same reaction as in Example 3 was carried out using 100 mg of the compound (6) and-7 'D-morph I-net // 200 # 1) to obtain 25 mg (23%) of the target compound (18) as a white powder. Obtained.
- Example 4 The same reaction as in Example 4 was carried out using 120 mg of compound (6) and 3-mt) T 't / W human' (200 / ⁇ 1), and the target compound (19) was converted into a white powder of 105 mi ( 79%).
- Example 4 The same reaction as in Example 4 was carried out using 150 mg of this compound and 100 mg of compound (6) to obtain an N-substituted product (90 nig), which was dissolved in methanol (3 ml) to give 28% sodium; -Tano- solution (01 ml) was added, and the mixture was stirred at room temperature for 3 hours.After confirming the completion of the reaction by TLC, the mixture was neutralized with 2 N hydrochloric acid and depressurized, and the residue was dissolved in water. -After washing with tellurium, the aqueous layer was squeezed under reduced pressure.
- LiChroprep RP18, 30% methanol was eluted with water from the mixture of water to obtain 55 mg of the dehydrogenated / isomer. This was dissolved in 5 ml of methanol and 1 ml of acetic acid. Add 50 mg of Rashi-Dumf Lakku, stir at room temperature for 3 hours, and perform contact hydrogenation. Separate the Rashi-Dumf Lakku, wash with Etano, and combine the liquid and the wash liquid. The concentrate was concentrated under reduced pressure, and the resulting residue was subjected to column chromatography (LiChraprep RP18, elution with 30% metal from water) to obtain 22 mg (18%) of compound (20).
- Example 4 The same reaction as in Example 4 was carried out using 200 mg of compound (6), 3- (n-hexanoamide) a of if and do (ISOmg) to obtain the desired compound (23) as a white powder. 160 mg (63%) were obtained.
- Example 4 The same reaction as in Example 4 was carried out using 200 mg of the compound (6) and 3- (n-octanesulfonamide:) arohi'onarte'human '(246 mg) to give the desired compound (25) as a white powder 183 mg (65%)
- Example 4 The same anti-JS as in Example 4 was carried out using 700 mg of compound (6) and Tote Wf IV (U5 ml) to obtain 0 mg (68.5%) of target compound (26) as a white powder.
- the purified product is dissolved in a small amount of water, desalted with acid -'- (force-trish '; ⁇ ⁇ -20), freeze-dried, and 240 mg (33.3%) of the desired compound (27) is obtained as a white powder. %)Obtained.
- the reaction mixture was vacuumed and subjected to column chromatography ⁇ -mat (Wakogel C300, eluent acid ⁇ ///, 2: 1 elution with ethyl acetate) and colorless dye D Kufu'-like compound S- [2- (2-1 ethoxyethoxy) ethoxycarboyleneamino] fuu / real alcohol (6.5 g, 56%) was obtained.
- Compound (36) 1. was dissolved in a 50% aqueous solution of ethanol (64 ml), a 2N aqueous sodium hydroxide solution (8.5 ml) was added, and the mixture was stirred at 90 ° C. for 6 hours. Neutralize with an aqueous solution, compress under reduced pressure, apply the resulting residue to column chromatography 'Raffi- (LiChroprep RP-18, eluent; water), desalinate the product with Azylisa'- Lyophilization yielded 0.9 g (47.4%) of compound (37).
- Example 4 The same reaction as in Example 4 was carried out using 100 mg of the compound (37) and ⁇ -talactyl aldehyde (1331) to obtain 89 mg (76.3%) of the desired compound (38) as a white powder.
- Example 4 The same reaction as in Example 4 was carried out using 200 mg of compound (37) and 1-to-the-canal (3741) to obtain 11 lmg (44.1%) of the desired compound (39) as a white powder.
- Example 4 The same reaction as in Example 4 was carried out using 200 mg of compound (37) and 1-to-the-canal (3741) to obtain 11 lmg (44.1%) of the desired compound (39) as a white powder.
- Example 4 The same reaction as in Example 4 was performed using 100 mg of the compound (37) and 100 mg of ril realte hydride to obtain 99 mg (70.6%) of the desired compound (40) as a white powder.
- HUVEC> human vascular endothelial cells
- HUVEC> 1% Se' co with keratin - you encountered a 96-well microphone Pai7 'Uyuru per 2 ⁇ 10 4 Les DOO . pieces were seeded 37.C of C0 2 ink: to I '- after over ⁇ cultured in data, RPMVFCS / HEPES medium the cell layer 100 ⁇ 1 (RPMMI-1640, 10% F CS, 25mM HEPES, pH7 Wash twice with .4), and add lOU / ml of I: l ⁇ containing RFMI / FCS / HEPES to 100
- a kit containing only RPMI / FCS HEFES alone (KBasal) was prepared. After washing twice with RFMI-1640 (RFMI HEFES) that does not contain FCS, Susan human leukemia cells HL60 are suspended in 10 ml of RFMI / FCS / HEPES medium containing 0.5% tartaraldehyde, and placed on ice. Fixed for 20 minutes.
- the cells were washed three times with RPMI / H EPES, diluted with RPMI FCS / HEFES so that the cell number was 2 ⁇ 10 8 ⁇ 11 ⁇ / 111 ⁇ , and stored on ice until use. .
- the HUVECs were washed three times with 100 ⁇ l of RPMI / FCS / HEPES, and each compound of I dissolved in 50 # 1 RPMI / FCS / HEFES (Control) and RPMI / FCS / HEPES (lms / ml ) Or anti-E-selectin antibody (25 ⁇ g ml), and incubate at room temperature for 30 minutes.
- 1 ⁇ 10 5 (50 ml) of the immobilized HL60 cells were added to each cell, and the cells were incubated at room temperature for 45 minutes. Fill each chill with RPMI FCS / H EPES, seal it with a miter Dale seal so that no air bubbles enter, then let the plate fall and let stand for 1 hour To remove unbound HL60 cells.
- the number of adherent cells was determined based on the activity of mi-It'luxita'-ze (MPO), an enzyme present in HL60 cells. Add 0.5% hexadecid bromide to each well; add 1 ⁇ _timonicum (HTAB>! Acid buffer (50 mM, pH 6.0) and incubate at room temperature for 30 minutes to remove ⁇ Solubilized from within O 97/00881
- Anti-E-seletin antibody 6 4.2 ⁇ 1.1
- Plasma Platelet Rich Plasma, (PRP) O 97/00881
- Incubator i Effect on leukemia cell HL60 on PIN-dependent adhesion (2) Test compound Portability (mg ml) n Cell adhesion rate f%)
- the compounds according to the present invention exhibited remarkable cell adhesion inhibitory activity against perylene and ⁇ -selen. From the above, it can be seen that the compound of the present invention inhibits the adhesion between leukocytes or cells and endothelial cells by competitively inhibiting secretin present in endothelial cells. O 97/00881
- the compound of the present invention When the compound of the present invention is administered as a medicament, the compound of the present invention contains 0.19 & 99.5%, preferably 0.5%-90% as it is or in a pharmaceutically acceptable non-toxic and inert carrier. As a composition, it can be administered to animals containing humans.
- the carrier one or more solid, semi-solid, or liquid diluents, fillers, and other formulation auxiliaries are used.
- the pharmaceutical compositions are administered in dosage unit form.
- the pharmaceutical composition of the present invention can be administered in a tissue, topically (eg, transdermally), or rectally. It is needless to say that the composition is administered in a dosage form suitable for these administration methods. For example, intra-tissue administration is particularly preferred.
- the dosage as an anti-inflammatory agent is desirably prepared in consideration of the patient's condition such as age, body weight, etc., the administration route, the nature and extent of the disease, and the like.
- the amount of the ingredient is generally in the range of 100 mg to 3 g / day / human, preferably in the range of 500 mg to: lg / day / human per day. In some cases, lower doses may be sufficient and conversely, higher doses may be required. It is also desirable to administer the drug in 1 to 3 divided doses a day. The same applies to other pharmaceutical uses.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des dérivés de la moranoline représentés par la formule développée (I). Dans cette formule, R1 représente un alkyle inférieur substitué par un acyle, alcoxycarbonyle, cyano, alkylcarbamoyle, nitro, acylamino, alkylthio, hydroxy ou aryloxy, phényl-alkyle inférieur où le noyau benzénique porte éventuellement des substituants tels que hydroxy, alcoxy inférieur, alkyle inférieur, halogéno, cyano, alkyl(inférieur)carbamoyle, nitro, acylamino, alkylthio ou carboxy, alkyle inférieur substitué par un hétérocycle insaturé à 5 éléments éventuellement substitué par un alkyle inférieur, alcényle, arylalcényle ou alkyle supérieur; R2 et R3 sont différents et chacun représente un galactopyranosyle ou un fucopyranosyle substitué par un hydroxysulfonyle ou un sel de celui-ci; et R4 représente un hydroxy ou un acétamide. Ces composés sont utiles dans le domaine médical, par exemple comme agents anti-inflammatoires ou pour le traitement préventif ou curatif de l'ischémie et de troubles circulatoires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7/155776 | 1995-06-22 | ||
JP15577695 | 1995-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997000881A1 true WO1997000881A1 (fr) | 1997-01-09 |
Family
ID=15613163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/001730 WO1997000881A1 (fr) | 1995-06-22 | 1996-06-21 | Derives de la moranoline |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1997000881A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997048712A1 (fr) * | 1996-06-17 | 1997-12-24 | Nippon Shinyaku Co., Ltd. | Derives asialotrisaccharide moranoline et medicaments |
WO1998041214A1 (fr) * | 1997-03-14 | 1998-09-24 | Nippon Shinyaku Co., Ltd. | Medicaments contre les troubles ischemiques de reperfusion |
WO1998051315A1 (fr) * | 1997-05-12 | 1998-11-19 | Nippon Shinyaku Co., Ltd. | Agent therapeutique pour rhumatismes articulaires |
US6225325B1 (en) | 1997-11-10 | 2001-05-01 | G.D. Searle & Company | Use of alkylated iminosugars to treat multidrug resistance |
US6515028B1 (en) | 1999-02-12 | 2003-02-04 | G.D. Searle & Co. | Glucamine compounds for treating hepatitis virus infections |
US6545021B1 (en) | 1999-02-12 | 2003-04-08 | G.D. Searle & Co. | Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
US6689759B1 (en) | 1998-02-12 | 2004-02-10 | G. D. Searle & Co. | Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy |
US6809083B1 (en) | 1998-02-12 | 2004-10-26 | Richard A. Mueller | Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections |
EP1903034A1 (fr) * | 2006-09-19 | 2008-03-26 | Technische Universität Graz | Iminosucres glycoconjugués |
US7612093B2 (en) | 1997-02-14 | 2009-11-03 | United Therapeutics Corporation | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993015098A1 (fr) * | 1992-01-31 | 1993-08-05 | Nippon Shinyaku Co., Ltd. | Derive d'une chaine de sucre du type lewis |
WO1994000477A1 (fr) * | 1992-06-29 | 1994-01-06 | Glycomed Incorporated | Derives de lactose substitues utilises comme inhibiteurs d'adhesion cellulaire |
-
1996
- 1996-06-21 WO PCT/JP1996/001730 patent/WO1997000881A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993015098A1 (fr) * | 1992-01-31 | 1993-08-05 | Nippon Shinyaku Co., Ltd. | Derive d'une chaine de sucre du type lewis |
WO1994000477A1 (fr) * | 1992-06-29 | 1994-01-06 | Glycomed Incorporated | Derives de lactose substitues utilises comme inhibiteurs d'adhesion cellulaire |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997048712A1 (fr) * | 1996-06-17 | 1997-12-24 | Nippon Shinyaku Co., Ltd. | Derives asialotrisaccharide moranoline et medicaments |
US7612093B2 (en) | 1997-02-14 | 2009-11-03 | United Therapeutics Corporation | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy |
WO1998041214A1 (fr) * | 1997-03-14 | 1998-09-24 | Nippon Shinyaku Co., Ltd. | Medicaments contre les troubles ischemiques de reperfusion |
WO1998051315A1 (fr) * | 1997-05-12 | 1998-11-19 | Nippon Shinyaku Co., Ltd. | Agent therapeutique pour rhumatismes articulaires |
US6225325B1 (en) | 1997-11-10 | 2001-05-01 | G.D. Searle & Company | Use of alkylated iminosugars to treat multidrug resistance |
US6689759B1 (en) | 1998-02-12 | 2004-02-10 | G. D. Searle & Co. | Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy |
US6809083B1 (en) | 1998-02-12 | 2004-10-26 | Richard A. Mueller | Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections |
US6515028B1 (en) | 1999-02-12 | 2003-02-04 | G.D. Searle & Co. | Glucamine compounds for treating hepatitis virus infections |
US6545021B1 (en) | 1999-02-12 | 2003-04-08 | G.D. Searle & Co. | Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
US6747149B2 (en) | 1999-02-12 | 2004-06-08 | G. D. Searle & Co. | Glucamine salts for treating hepatitis virus infections |
EP1903034A1 (fr) * | 2006-09-19 | 2008-03-26 | Technische Universität Graz | Iminosucres glycoconjugués |
WO2008034575A1 (fr) * | 2006-09-19 | 2008-03-27 | Technische Universität Graz | Glycoconjugués iminosucres |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2590248B2 (ja) | 抗ウイルス・抗腫瘍・抗転移・免疫系増強ヌクレオシド類およびヌクレオチド類 | |
WO2002024754A1 (fr) | Polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine | |
WO1994009020A1 (fr) | Nouveau shingoglycolipide et son utilisation | |
CN102112484A (zh) | 三萜皂苷、其合成方法和用途 | |
WO1982001873A1 (fr) | Derives 1-sulfo-2-oxoazetidine et leur procede de preparation | |
WO1997000881A1 (fr) | Derives de la moranoline | |
US4849563A (en) | Novel 1-alkyl-1-arenesulfonyl-2-alkoxycarbonylsulfenylhydrazines having antineoplastic activity | |
JPS61191669A (ja) | 抗新生物活性を有するn,n′‐ビス(スルホニル)ヒドラジン | |
AU2834200A (en) | Chemical compounds | |
DK163585B (da) | Retinoidcarboxylsyre-mono- og -disaccharidestere, disse estere til anvendelse som laegemidler, isaer til behandling af neoplasi, acne eller psoriasis, fremgangsmaade til fremstilling deraf, farmaceutiske praeparater indeholdende disse estere samt anvendelse af esterne til fremstilling af et middel til behandling af neoplasi, acne eller psoriasis | |
EP1172107A1 (fr) | Medicaments contenant des derives du sulfopyranosylacylglycerol | |
HUE033210T2 (hu) | Rákellenes aktivitású 2-dezoxi-monoszacharidok új acetátjai | |
JPH07502011A (ja) | 免疫抑制性および寛容原性のオリゴ糖誘導体 | |
EP0338092A1 (fr) | Agent anti-vih | |
JP2001097867A (ja) | 皮脂産生抑制剤 | |
CA2577258C (fr) | Hexadecasaccharides biotinyles, leur preparation et leur utilisation comme anticoagulants et antithrombotique de l'heparine | |
JP2005041817A (ja) | クルクミノイド配糖体、及びその製造方法 | |
US4962114A (en) | 1-alkyl-1-sulfonyl-2-alkoxycarbonylsulfenylhydrazines having antineoplastic activity | |
JPS61176598A (ja) | シチジン−ジホスフエ−ト−コリンのアシル化誘導体、その製造方法及びその治療的使用 | |
CA2771055C (fr) | Oligosaccharides n-sulfates activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique | |
JP4811953B2 (ja) | α−N−アセチルグルコサミニル結合単糖誘導体を含有するピロリ菌増殖抑制剤 | |
US5700918A (en) | Moranoline derivative | |
JP5788653B2 (ja) | 糖鎖修飾ヌクレオチド及びその使用 | |
JP2022529855A (ja) | グリセロ-マンノ-ヘプトースホスフェートの誘導体および免疫応答をモジュレートする際のそれらの使用 | |
JP4143169B2 (ja) | ノジリマイシン亜硫酸付加物のアシル化物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |